Beigene Stock Price, News & Analysis (NASDAQ:BGNE)

$155.96 +0.06 (+0.04 %)
(As of 02/25/2018 12:46 PM ET)
Previous Close$155.96
Today's Range$147.02 - $159.89
52-Week Range$34.36 - $164.15
Volume333,837 shs
Average Volume332,605 shs
Market Capitalization$8.23 billion
P/E Ratio-119.97
Dividend YieldN/A
Beta0.61

About Beigene (NASDAQ:BGNE)

Beigene logoBeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). BGB-283 is a molecule inhibitor of both the monomer and dimer forms of the RAF kinase. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of the poly ADP ribose polymerase (PARP) family members. BGB-A317 is an investigational humanized monoclonal antibody against the immune checkpoint receptor, PD-1.

Receive BGNE News and Ratings via Email

Sign-up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BGNE
CUSIPN/A
Phone34-59-494-12

Debt

Debt-to-Equity Ratio0.20%
Current Ratio9.33%
Quick Ratio9.27%

Price-To-Earnings

Trailing P/E Ratio-119.969230769231
Forward P/E Ratio-76.45
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.07 million
Price / Sales7,694.51
Cash FlowN/A
Price / CashN/A
Book Value$11.20 per share
Price / Book13.93

Profitability

Trailing EPS($1.30)
Net Income$-119,210,000.00
Net MarginsN/A
Return on Equity-7.40%
Return on Assets-5.44%

Miscellaneous

Employees322
Outstanding Shares52,790,000

Beigene (NASDAQ:BGNE) Frequently Asked Questions

What is Beigene's stock symbol?

Beigene trades on the NASDAQ under the ticker symbol "BGNE."

How were Beigene's earnings last quarter?

Beigene Ltd (NASDAQ:BGNE) announced its quarterly earnings results on Monday, November, 13th. The company reported $2.54 EPS for the quarter, beating the Zacks' consensus estimate of $0.23 by $2.31. The company earned $220.21 million during the quarter, compared to analyst estimates of $1.55 million. During the same quarter last year, the company posted ($1.08) EPS. View Beigene's Earnings History.

When will Beigene make its next earnings announcement?

Beigene is scheduled to release their next quarterly earnings announcement on Tuesday, March, 20th 2018. View Earnings Estimates for Beigene.

Where is Beigene's stock going? Where will Beigene's stock price be in 2018?

7 brokers have issued twelve-month target prices for Beigene's stock. Their forecasts range from $81.00 to $120.00. On average, they expect Beigene's stock price to reach $93.00 in the next twelve months. View Analyst Ratings for Beigene.

What are Wall Street analysts saying about Beigene stock?

Here are some recent quotes from research analysts about Beigene stock:

  • 1. Maxim Group analysts commented, "BeiGene announced the commercial availability of Celgene’s VIDAZA. Recall that VIDAZA is an injectable nucleoside metabolic inhibitor for patients with Intermediate-2/high-risk myelodysplastic syndrome (MDS), AML with 20-30% bone marrow blasts and chronic myelomonocyte leukemia (CMML). The asset is the third product in BeiGene’s China commercial portfolio along with Abraxane and Revlimid and positions BeiGene to be a leader in the oncology space in China." (2/7/2018)
  • 2. According to Zacks Investment Research, "BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. " (1/30/2018)
  • 3. Cowen Inc analysts commented, "SGMO reported 3Q17 results and is on track to report first data from the Ph1/2 trials." (11/14/2017)

Who are some of Beigene's key competitors?

Who are Beigene's key executives?

Beigene's management team includes the folowing people:

  • John V Oyler, Chairman of the Board, Chief Executive Officer, Founder (Age 48)
  • Howard Liang Ph.D., Chief Financial Officer and Chief Strategy Officer (Age 52)
  • Wendy Yan, Senior Vice President, Head of Regulatory Affairs (Age 50)
  • Jason Yang M.D.Suffix is Ph.D., Senior Vice President, Head of Clinical Development (Age 51)
  • Timothy Y. Chen, Director (Age 59)
  • Donald W. Glazer, Director (Age 71)
  • Michael J. Goller, Director (Age 40)
  • Ranjeev Krishana, Director (Age 41)
  • Xiaodong Wang Ph.D., Director (Age 52)

When did Beigene IPO?

(BGNE) raised $126 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

Who owns Beigene stock?

Beigene's stock is owned by many different of retail and institutional investors. Top institutional investors include OppenheimerFunds Inc. (1.21%), Alliancebernstein L.P. (0.82%), BlackRock Inc. (0.68%), Prince Street Capital Management LLC (0.66%), Artal Group S.A. (0.57%) and Brown Advisory Inc. (0.56%). Company insiders that own Beigene stock include Amy C Peterson, Bros Advisors Lp Baker, Donald W Glazer, Jane Huang, John Oyler, Thomas Malley and Xiaodong Wang. View Institutional Ownership Trends for Beigene.

Who sold Beigene stock? Who is selling Beigene stock?

Beigene's stock was sold by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Alliancebernstein L.P., Brown Advisory Inc., First Trust Advisors LP, Deutsche Bank AG, Rock Springs Capital Management LP, Guggenheim Capital LLC and Vident Investment Advisory LLC. Company insiders that have sold Beigene company stock in the last year include Amy C Peterson, Donald W Glazer, Jane Huang, John Oyler and Xiaodong Wang. View Insider Buying and Selling for Beigene.

Who bought Beigene stock? Who is buying Beigene stock?

Beigene's stock was bought by a variety of institutional investors in the last quarter, including Artal Group S.A., Horseman Capital Management Ltd, Employees Retirement System of Texas, Allianz Asset Management GmbH, Tekla Capital Management LLC, Goldman Sachs Group Inc., BlackRock Inc. and Teachers Retirement System of The State of Kentucky. Company insiders that have bought Beigene stock in the last two years include Bros Advisors Lp Baker and Thomas Malley. View Insider Buying and Selling for Beigene.

How do I buy Beigene stock?

Shares of Beigene can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Beigene's stock price today?

One share of Beigene stock can currently be purchased for approximately $155.96.

How big of a company is Beigene?

Beigene has a market capitalization of $8.23 billion and generates $1.07 million in revenue each year. The company earns $-119,210,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis. Beigene employs 322 workers across the globe.

How can I contact Beigene?

Beigene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 34-59-494-12 or via email at [email protected]


MarketBeat Community Rating for Beigene (BGNE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  185 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  339
MarketBeat's community ratings are surveys of what our community members think about Beigene and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Beigene (NASDAQ:BGNE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.862.863.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $93.00$93.00$93.00$76.20
Price Target Upside: 25.60% downside17.46% downside16.83% upside8.90% upside

Beigene (NASDAQ:BGNE) Consensus Price Target History

Price Target History for Beigene (NASDAQ:BGNE)

Beigene (NASDAQ:BGNE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/7/2018Maxim GroupReiterated RatingBuyLowView Rating Details
1/8/2018CowenReiterated RatingBuyHighView Rating Details
11/14/2017Robert W. BairdReiterated RatingOutperform -> Neutral$58.00 -> $83.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingOverweight$87.00 -> $95.00N/AView Rating Details
8/15/2017Goldman Sachs GroupReiterated RatingBuy$43.00 -> $86.00LowView Rating Details
8/7/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$81.00HighView Rating Details
6/1/2017William BlairReiterated RatingOutperformLowView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Beigene (NASDAQ:BGNE) Earnings History and Estimates Chart

Earnings by Quarter for Beigene (NASDAQ:BGNE)

Beigene (NASDAQ BGNE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/20/2018($1.76)N/AView Earnings Details
11/13/2017Q3$0.23$2.54$1.55 million$220.21 millionViewN/AView Earnings Details
8/9/2017Q2 2017($1.21)($1.52)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.97)($1.27)ViewN/AView Earnings Details
3/22/2017Q4($0.86)($1.05)$3.75 million$1.00 millionViewN/AView Earnings Details
11/10/2016Q316($0.78)($1.08)$1.88 millionViewN/AView Earnings Details
8/10/2016Q2($0.68)($0.73)$2.08 million$0.40 millionViewN/AView Earnings Details
5/11/2016Q1($0.05)($0.97)$0.70 millionViewN/AView Earnings Details
3/30/2016Q4($1.06)($3.05)$1.74 million$4.68 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Beigene (NASDAQ:BGNE) Earnings Estimates

2018 EPS Consensus Estimate: ($7.55)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($2.11)($2.11)($2.11)
Q2 20181($2.14)($2.14)($2.14)
Q3 20181($2.18)($2.18)($2.18)
Q4 20181($1.12)($1.12)($1.12)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Beigene (NASDAQ:BGNE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Beigene (NASDAQ BGNE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.90%
Institutional Ownership Percentage: 49.35%
Insider Trades by Quarter for Beigene (NASDAQ:BGNE)
Institutional Ownership by Quarter for Beigene (NASDAQ:BGNE)

Beigene (NASDAQ BGNE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/18/2018Bros. Advisors Lp BakerDirectorBuy1,980,198$101.00$199,999,998.00View SEC Filing  
12/26/2017John OylerCEOSell20,137$96.46$1,942,415.02110,179View SEC Filing  
12/21/2017Jane HuangCMOSell1,000$98.00$98,000.001,000View SEC Filing  
12/13/2017Jane HuangCMOSell1,500$94.25$141,375.001,500View SEC Filing  
12/8/2017John OylerCEOSell144,000$93.95$13,528,800.00255,137View SEC Filing  
12/6/2017John OylerCEOSell31,446$92.29$2,902,151.34255,137View SEC Filing  
12/4/2017Jane HuangCMOSell1,100$86.00$94,600.00264,900View SEC Filing  
11/29/2017John OylerCEOSell85,906$84.66$7,272,801.96332,697View SEC Filing  
11/27/2017John OylerCEOSell16,581$86.76$1,438,567.56332,697View SEC Filing  
11/20/2017Jane HuangCMOSell1,600$86.25$138,000.00264,900View SEC Filing  
11/16/2017Jane HuangCMOSell600$85.00$51,000.00264,900View SEC Filing  
11/15/2017John OylerCEOSell150,957$80.50$12,152,038.50491,891View SEC Filing  
11/13/2017Amy C PetersonCMOSell3,601$82.96$298,738.961,201View SEC Filing  
11/13/2017John OylerCEOSell25,054$83.06$2,080,985.24491,891View SEC Filing  
8/11/2017Bros. Advisors Lp BakerDirectorBuy176,056$71.00$12,499,976.00View SEC Filing  
7/12/2017Xiaodong WangDirectorSell20,000$72.44$1,448,800.0016,300View SEC Filing  
7/10/2017Donald W GlazerDirectorSell10,810$72.15$779,941.507,206View SEC Filing  
7/6/2017John OylerCEOSell219,400$64.82$14,221,508.00212,055View SEC Filing  
6/28/2017Xiaodong WangDirectorSell35,000$44.95$1,573,250.0026,600View SEC Filing  
6/23/2017John OylerCEOSell98,500$44.16$4,349,760.0088,535View SEC Filing  
6/2/2017Xiaodong WangDirectorSell5,539$40.00$221,560.0055,000View SEC Filing  
5/4/2017Xiaodong WangDirectorSell14,461$40.80$590,008.8065,030View SEC Filing  
5/1/2017John OylerCEOSell36,149$40.47$1,462,950.03147,440View SEC Filing  
4/5/2017Xiaodong WangDirectorSell11,650$36.83$429,069.5081,194View SEC Filing  
3/24/2017Xiaodong WangDirectorSell38,107$36.96$1,408,434.72116,478View SEC Filing  
3/20/2017John OylerCEOSell31,989$39.39$1,260,046.71197,640View SEC Filing  
3/10/2017Xiaodong WangDirectorSell36,892$39.89$1,471,621.88150,657View SEC Filing  
3/6/2017John OylerCEOSell108,999$40.91$4,459,149.09273,385View SEC Filing  
2/27/2017Xiaodong WangDirectorSell38,351$38.19$1,464,624.69194,495View SEC Filing  
2/21/2017John OylerCEOSell64,963$40.55$2,634,249.65378,383View SEC Filing  
11/23/2016Thomas MalleyDirectorBuy30,000$32.00$960,000.0030,000View SEC Filing  
11/18/2016Bros. Advisors Lp BakerDirectorBuy1,760,495$32.00$56,335,840.00View SEC Filing  
9/28/2016Donald W GlazerDirectorSell41,463$30.66$1,271,255.584,881,997View SEC Filing  
9/27/2016Donald W GlazerDirectorSell47,149$29.61$1,396,081.894,881,997View SEC Filing  
9/23/2016Donald W GlazerDirectorSell36,443$31.02$1,130,461.864,881,997View SEC Filing  
9/21/2016Donald W GlazerDirectorSell67,252$31.42$2,113,057.844,882,000View SEC Filing  
2/8/2016Bros. Advisors Lp BakerDirectorBuy1,912,680$24.00$45,904,320.00View SEC Filing  
2/8/2016Howard LiangCFOBuy65,000$1.85$120,250.0065,000View SEC Filing  
2/8/2016Ruirong YuanInsiderBuy130,000$1.85$240,500.00130,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Beigene (NASDAQ BGNE) News Headlines

Source:
DateHeadline
40,000 Shares in Beigene Ltd (BGNE) Acquired by Employees Retirement System of Texas40,000 Shares in Beigene Ltd (BGNE) Acquired by Employees Retirement System of Texas
www.americanbankingnews.com - February 25 at 5:26 AM
Beigene Ltd (BGNE) Holdings Reduced by Brown Advisory Inc.Beigene Ltd (BGNE) Holdings Reduced by Brown Advisory Inc.
www.americanbankingnews.com - February 24 at 2:46 PM
These 2 Biotech Stocks Are Soaring. Can They Keep It Up?These 2 Biotech Stocks Are Soaring. Can They Keep It Up?
finance.yahoo.com - February 23 at 9:23 AM
Beigene Ltd (BGNE) Receives Consensus Rating of "Buy" from BrokeragesBeigene Ltd (BGNE) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 20 at 12:49 PM
Beigene Ltd (BGNE) Expected to Post Quarterly Sales of $23.00 MillionBeigene Ltd (BGNE) Expected to Post Quarterly Sales of $23.00 Million
www.americanbankingnews.com - February 12 at 2:58 AM
BeiGene (BGNE) Presents Preliminary Phase 1 Data on Tislelizumab in Patients with UCBeiGene (BGNE) Presents Preliminary Phase 1 Data on Tislelizumab in Patients with UC
www.streetinsider.com - February 11 at 9:04 AM
BeiGene Presents Preliminary Phase 1 Data on Tislelizumab in Patients with Urothelial Carcinoma at 2018 Genitourinary Cancers SymposiumBeiGene Presents Preliminary Phase 1 Data on Tislelizumab in Patients with Urothelial Carcinoma at 2018 Genitourinary Cancers Symposium
finance.yahoo.com - February 9 at 5:24 PM
Beigenes (BGNE) Buy Rating Reaffirmed at Maxim GroupBeigene's (BGNE) Buy Rating Reaffirmed at Maxim Group
www.americanbankingnews.com - February 7 at 12:51 PM
BeiGene to Present at the LEERINK Partners 7th Annual Global Healthcare ConferenceBeiGene to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 7 at 9:13 AM
BeiGene to Present Tislelizumab Data in Urothelial Carcinoma at the 2018 Genitourinary Cancers SymposiumBeiGene to Present Tislelizumab Data in Urothelial Carcinoma at the 2018 Genitourinary Cancers Symposium
finance.yahoo.com - February 6 at 9:08 AM
BeiGene Announces Commercial Availability of VIDAZA® (Azacitidine for Injection) in ChinaBeiGene Announces Commercial Availability of VIDAZA® (Azacitidine for Injection) in China
finance.yahoo.com - February 6 at 9:08 AM
Here's Why BeiGene, Ltd. Jumped 38.9% in JanuaryHere's Why BeiGene, Ltd. Jumped 38.9% in January
finance.yahoo.com - February 5 at 4:23 PM
Blog Exposure - BeiGene Commenced Dosing in Global Phase-3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with ESCCBlog Exposure - BeiGene Commenced Dosing in Global Phase-3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with ESCC
finance.yahoo.com - February 2 at 9:10 AM
BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Esophageal Squamous Cell CarcinomaBeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Esophageal Squamous Cell Carcinoma
finance.yahoo.com - January 31 at 9:23 AM
Beigene (BGNE) Upgraded at Zacks Investment ResearchBeigene (BGNE) Upgraded at Zacks Investment Research
www.americanbankingnews.com - January 30 at 5:56 PM
Benzingas Insider Buys Of The Week: BeiGene, Opko Health And MoreBenzinga's Insider Buys Of The Week: BeiGene, Opko Health And More
feeds.benzinga.com - January 27 at 6:30 PM
Beigene Ltd (BGNE) Given Consensus Recommendation of "Hold" by BrokeragesBeigene Ltd (BGNE) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 26 at 9:48 AM
Celgene's Investments Are SoaringCelgene's Investments Are Soaring
finance.yahoo.com - January 23 at 8:18 AM
Beigene Ltd (BGNE) Director Bros. Advisors Lp Baker Purchases 1,980,198 SharesBeigene Ltd (BGNE) Director Bros. Advisors Lp Baker Purchases 1,980,198 Shares
www.americanbankingnews.com - January 22 at 6:34 PM
BeiGene Announces Closing of $800 Million Public OfferingBeiGene Announces Closing of $800 Million Public Offering
finance.yahoo.com - January 22 at 5:51 PM
BeiGene (BGNE) Surges: Stock Moves 12.6% HigherBeiGene (BGNE) Surges: Stock Moves 12.6% Higher
finance.yahoo.com - January 19 at 10:20 AM
Investors Cheer BeiGene’s Secondary OfferingInvestors Cheer BeiGene’s Secondary Offering
finance.yahoo.com - January 18 at 5:08 PM
BeiGene Announces Proposed Public OfferingBeiGene Announces Proposed Public Offering
finance.yahoo.com - January 16 at 5:29 PM
Beigene (BGNE) Cut to Hold at BidaskClubBeigene (BGNE) Cut to Hold at BidaskClub
www.americanbankingnews.com - January 13 at 5:38 PM
BeiGene (BGNE), Boehringer Ingelheim Enter Commercial Supply Agreement for Anti-PD-1 Antibody TislelizumabBeiGene (BGNE), Boehringer Ingelheim Enter Commercial Supply Agreement for Anti-PD-1 Antibody Tislelizumab
www.streetinsider.com - January 9 at 5:39 PM
BeiGene and Boehringer Ingelheim Announce Commercial Supply Agreement for Anti-PD-1 Antibody TislelizumabBeiGene and Boehringer Ingelheim Announce Commercial Supply Agreement for Anti-PD-1 Antibody Tislelizumab
finance.yahoo.com - January 9 at 9:20 AM
Zacks Investment Research Downgrades Beigene (BGNE) to SellZacks Investment Research Downgrades Beigene (BGNE) to Sell
www.americanbankingnews.com - January 8 at 8:36 PM
Beigenes (BGNE) "Buy" Rating Reiterated at CowenBeigene's (BGNE) "Buy" Rating Reiterated at Cowen
www.americanbankingnews.com - January 8 at 4:44 PM
-$1.74 Earnings Per Share Expected for Beigene Ltd (BGNE) This Quarter-$1.74 Earnings Per Share Expected for Beigene Ltd (BGNE) This Quarter
www.americanbankingnews.com - January 7 at 7:26 PM
Harbour BioMed Announces Multi-Year Transgenic Platform Licensing Agreement with BeiGene for Fully Human Monoclonal Antibody Drug DiscoveryHarbour BioMed Announces Multi-Year Transgenic Platform Licensing Agreement with BeiGene for Fully Human Monoclonal Antibody Drug Discovery
www.streetinsider.com - January 7 at 10:17 AM
Beigene (BGNE) Stock Rating Upgraded by BidaskClubBeigene (BGNE) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - January 6 at 12:30 PM
Maxim Group Analysts Give Beigene (BGNE) a $120.00 Price TargetMaxim Group Analysts Give Beigene (BGNE) a $120.00 Price Target
www.americanbankingnews.com - January 3 at 8:00 PM
BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Hepatocellular CarcinomaBeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Hepatocellular Carcinoma
finance.yahoo.com - January 2 at 9:16 AM
Beigene Ltd (BGNE) Given Average Rating of "Buy" by BrokeragesBeigene Ltd (BGNE) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 1 at 9:56 AM
Beigene Ltd (BGNE) CEO Sells $1,942,415.02 in StockBeigene Ltd (BGNE) CEO Sells $1,942,415.02 in Stock
www.americanbankingnews.com - December 28 at 6:32 PM
Beigene Ltd (BGNE) Expected to Announce Quarterly Sales of $23.00 MillionBeigene Ltd (BGNE) Expected to Announce Quarterly Sales of $23.00 Million
www.americanbankingnews.com - December 24 at 10:02 AM
Insider Selling: Beigene Ltd (BGNE) CMO Sells 1,000 Shares of StockInsider Selling: Beigene Ltd (BGNE) CMO Sells 1,000 Shares of Stock
www.americanbankingnews.com - December 22 at 6:14 PM
-$1.74 EPS Expected for Beigene Ltd (BGNE) This Quarter-$1.74 EPS Expected for Beigene Ltd (BGNE) This Quarter
www.americanbankingnews.com - December 22 at 11:26 AM
Blog Exposure - BeiGene Announced Initiation of Pivotal Trial of PARP Inhibitor Pamiparib in Chinese Patients with Ovarian CancerBlog Exposure - BeiGene Announced Initiation of Pivotal Trial of PARP Inhibitor Pamiparib in Chinese Patients with Ovarian Cancer
finance.yahoo.com - December 20 at 9:15 AM
Beigene (BGNE) Given a $120.00 Price Target by Maxim Group AnalystsBeigene (BGNE) Given a $120.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - December 18 at 3:28 PM
BeiGene Initiates Pivotal Trial of PARP inhibitor Pamiparib (BGB-290) in China in Patients with Ovarian CancerBeiGene Initiates Pivotal Trial of PARP inhibitor Pamiparib (BGB-290) in China in Patients with Ovarian Cancer
finance.yahoo.com - December 18 at 9:29 AM
Jane Huang Sells 1,500 Shares of Beigene Ltd (BGNE) StockJane Huang Sells 1,500 Shares of Beigene Ltd (BGNE) Stock
www.americanbankingnews.com - December 15 at 6:32 PM
Cowen Reaffirms Buy Rating for Beigene (BGNE)Cowen Reaffirms Buy Rating for Beigene (BGNE)
www.americanbankingnews.com - December 12 at 3:16 PM
BeiGene (BGNE) Highlights Preliminary Phase 1b Data on BTK ... - StreetInsider.comBeiGene (BGNE) Highlights Preliminary Phase 1b Data on BTK ... - StreetInsider.com
www.streetinsider.com - December 11 at 5:45 PM
Celgenes Lymphoma Strategy Is Its Biggest Positive, Analyst SaysCelgene's Lymphoma Strategy Is Its Biggest Positive, Analyst Says
finance.yahoo.com - December 11 at 5:45 PM
BeiGene (BGNE) Reports Updated Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) Combined with GAZYVA (Obinutuzumab)BeiGene (BGNE) Reports Updated Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) Combined with GAZYVA (Obinutuzumab)
www.streetinsider.com - December 11 at 10:00 AM
BeiGene Presents Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) in Non-Hodgkin’BeiGene Presents Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) in Non-Hodgkin’
www.nasdaq.com - December 10 at 9:16 AM
Beigene Ltd (BGNE) CEO John Oyler Sold $13.5 million of SharesBeigene Ltd (BGNE) CEO John Oyler Sold $13.5 million of Shares
finance.yahoo.com - December 9 at 9:18 AM
BeiGene Presents Updated Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) Combined with GAZYVA® (Obinutuzumab) at the 59th American Society of Hematology Annual MeetingBeiGene Presents Updated Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) Combined with GAZYVA® (Obinutuzumab) at the 59th American Society of Hematology Annual Meeting
finance.yahoo.com - December 9 at 9:18 AM
John Oyler Sells 31,446 Shares of Beigene Ltd (BGNE) StockJohn Oyler Sells 31,446 Shares of Beigene Ltd (BGNE) Stock
www.americanbankingnews.com - December 8 at 11:16 PM

SEC Filings

Beigene (NASDAQ:BGNE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Beigene (NASDAQ:BGNE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Beigene (NASDAQ BGNE) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.